Blood Industry Reps Will Be Tapped Under “Realist” HHS Panel Approach
This article was originally published in The Gray Sheet
Executive Summary
HHS will restructure its Blood Safety & Availability Advisory Committee to openly acknowledge industry reps as panel members, rather than retain company employees with the use of regulatory waivers
You may also be interested in...
FDA Tags Academic Researcher To Probe Advisory Panel Conflicts Of Interest
A joint conflict-of-interest study by FDA and the University of Maryland will survey attendees at the agency's April Circulatory System Devices Advisory Panel and National Mammography Quality Assurance Advisory Committee meetings, according to the project's primary investigator
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.